ValiRx plc

Equities

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:10:16 17/05/2024 pm IST			5-day change	1st Jan Change
2.2 ^GBX	+15.79%		-27.87%	-62.71%

16/05	EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target	AN
15/05	Vertu Motors ups dividend as hails record revenue	AN

Valirx plc Reiterates Earnings Guidance for the Year 2024

April 24, 2024 at 04:54 pm IST

ValiRx plc reiterated earnings guidance for the year2024. Valmet reiterates its guidance issued on February 7, 2024, in which Valmet estimates that net sales in 2024 will remain at the previous year's level in comparison with 2023 (EUR 5,532 million).

Latest news about ValiRx plc

EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target	16/05	AN
Vertu Motors ups dividend as hails record revenue	15/05	AN
AIM WINNERS & LOSERS: Itim up on Majestic Wine contract renewal	15/05	AN
ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2023	15/05	CI
Valirx plc Reiterates Earnings Guidance for the Year 2024	24/04	CI
Valirx plc Announces Directorate Changes	22/04	CI
ValiRx inks evaluation deal with Imperial College London for research	21/03	AN
ValiRx plc Announces Signature of an Evaluation Agreement with Imperial College London	21/03	CI
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	20/03	AN
ValiRx Kick off Search for New CEO	19/03	MT
Valirx plc Announces Board Appointments, Subject to Completion of Regulatory Due Diligence	19/03	CI
EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	29/02	AN
Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director	29/02	CI
ValiRx Says Shareholder Group's Requisition Notice Invalid	13/02	MT
ValiRx says requisition notice from shareholder group is invalid	13/02	AN
ValiRx signs research sharing deal with Dundee University	12/02	AN
Valirx Signs Research, Evaluation Agreements with University of Dundee	12/02	MT
ValiRx plc Announces Agreement with Dundee Uni and Project Initiation	12/02	CI
ValiRx receives shareholder request for board change	10/02	AN
ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024	18/01	CI
ValiRx raises GBP192,200, part of wider GBP1.8 million raise	20/12	AN
Good Energy says ZapMap expands into mainland Europe	14/12	AN
ValiRx Signs Licensing Option Deal with Ambrose Healthcare	05/12	MT
ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose	05/12	AN
AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises	05/12	AN

Chart ValiRx plc

Duration

Period

More charts

Company Profile

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Sector

Biotechnology & Medical Research

Calendar

20/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALIRX PLC	-62.71%	3.7M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs